Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
1,973
datasets available to search
ShareScore release 0.9.0
Dataset results
1,973 results for “T cell receptor”
Dataset related to the article "Purinergic Receptor P2Y2 Stimulation Averts Aortic Valve Interstitial Cell Calcification and Myofibroblastic Activation"
<p>This record contains raw data related to the article "Purinergic Receptor P2Y2 Stimulation Averts Aortic Valve Interstitial Cell Calcification and Myofibroblastic Activation"</p> <p>Rationale-Calcific aortic valve stenosis (CAVS) is a pathological condition of the aortic valve with a prevalence of 3% in the general population. It is characterized by massive rearrangement of the extracellular matrix, mostly due to the accumulation of fibro-calcific deposits driven by valve interstitial cells (VIC), and no pharmacological treatment is currently available. The aim of this study was to evaluate the effects of P2Y2 receptor (P2RY2) activation on fibro-calcific remodeling of CAVS. Methods-We employed human primary VICs isolated from CAVS leaflets treated with 2-thiouridine-5'-triphosphate (2ThioUTP, 10 µM), an agonist of P2RY2. The calcification was induced by inorganic phosphate (2 mM) and ascorbic acid (50 µg/mL) for 7 or 14 days, while the 2ThioUTP was administered starting from the seventh day. 2ThioUTP was chronically administered for 5 days to evaluate myofibroblastic activation. Results-P2RY2 activation, under continuous or interrupted pro-calcific stimuli, led to a significant inhibition of VIC calcification potential (<em>p</em> < 0.01). Moreover, 2ThioUTP treatment was able to significantly reduce pro-fibrotic gene expression (<em>p</em> < 0.05), as well as that of protein α-smooth muscle actin (<em>p</em> = 0.004). Conclusions-Our data suggest that P2RY2 activation should be further investigated as a pharmacological target for the prevention of CAVS progression, acting on both calcification and myofibroblastic activation.</p>
B-cell receptor data from intratumoural B cells in melanoma patients
<p>This record contains data used in the Crescioli et al. analysis of B-cell response in melanoma, specifically analysis concerning high-throughput BCR repertoire.</p> <p>Files:</p> <p>"Visium_all_Aug22_comboDatBoth.txt": IMGT/HighV-Quest output of the high-throughput intratumoural BCR repertoire from n=5 melanoma tumours. In tab-separated text file format.</p> <p>"HV_EB_COV_MEL_comb_Oct22.RDS": A R data object (readable into R with "readRDS(...)") containing combined data from the melanoma (MEL) data with analogous high-throughput BCR repertoire data from healthy volunteers (HV), Ebola convalescent patients (EB) and hospitalised COVID-19 patients (COV). HV, EB and COV data are taken from <a href="https://dx.doi.org/10.5281/zenodo.5146019">https://dx.doi.org/10.5281/zenodo.5146019</a>. Here the sequences are filtered to contain only unique combinations of isotype and IMGT-numbered V-domain DNA sequence (to remove redundancies due to e.g. capturing BCR transcripts from plasma cells).</p> <p>"BM_Master_Light_Useasreftrue_140325_withPepStats_8.csv". IMGT/HighV-Quest output of the Bone Marrow light chain repertoire data. <a href="https://doi.org/10.3389/fimmu.2016.00388">Published in Townsend et al. Front Immunol 7:388 (2016)</a>. Used here for the comparison of gene conversion frequencies against the melanoma light chain repertoire.</p> <p>"BM_Master_Light_Useasreftrue_140325_withPepStats_8_Vgapped.fasta". The IMGT-gapped V-gene sequence from the Townsend et al. (see above) Bone Marrow light chain repertoire data. This is the raw input to BrepConvert. Provided here for this dataset; same sequences for the melanoma/healthy data are already in the RDS object ("HV_EB_COV_MEL_comb_Oct22.RDS").</p> <p>"2_IMGT-gapped-nt-sequences_visa.txt", "2_IMGT-gapped-nt-sequences_visb.txt": Raw output of IMGT/HighV-Quest containing IMGT-gapped nucleotide sequences. These files were parsed to extract the IMGT-gapped V-gene sequence for BrepConvert analysis.</p> <p>"BrepConvert.zip": BrepConvert gene conversion analysis results for Healthy and Melanoma repertoires.</p> <p>See code in <a href="https://github.com/josef0731/melanoma-ig">https://github.com/josef0731/melanoma-ig</a> for ways to use these input files for reproducing the analyses.</p> <p> </p>
Phase I/II Study of Autologous T Cells to Express T-Cell Receptors (TCRs) in Subjects With Solid Tumors
ClinicalTrials.gov study NCT05194735. IPD Sharing: NO. Countries: 1. Publications: 1.
Genetically Engineered Cells (MAGE-A1-specific T Cell Receptor-transduced Autologous T-cells) and Atezolizumab for the Treatment of Metastatic Triple Negative Breast Cancer, Urothelial Cancer, or Non-
ClinicalTrials.gov study NCT04639245. IPD Sharing: NO. Countries: 1. Publications: 1.
T Cell Receptor Immunotherapy Targeting MAGE-A3 for Patients With Metastatic Cancer Who Are HLA-DP0401 Positive
ClinicalTrials.gov study NCT02111850. IPD Sharing: NO. Countries: 1. Publications: 3.
A Phase 2 Open-Label Study of the Efficacy and Safety of ABT-199 (GDC-0199) in Chronic Lymphocytic Leukemia (CLL) Subjects With Relapse or Refractory to B-Cell Receptor Signaling Pathway Inhibitor The
ClinicalTrials.gov study NCT02141282. IPD Sharing: YES. Countries: 1. Publications: 3.
T Cell Receptor Immunotherapy Targeting NY-ESO-1 for Patients With NY-ESO-1 Expressing Cancer
ClinicalTrials.gov study NCT01967823. IPD Sharing: NO. Countries: 1. Publications: 3.
A Study of Lazertinib in Participants With Epidermal Growth Factor Receptor (EGFR) Mutation Positive Advanced Non-Small Cell Lung Cancer (NSCLC)
ClinicalTrials.gov study NCT04075396. IPD Sharing: YES. Countries: 3. Publications: 1.
Erlotinib Hydrochloride With or Without Bevacizumab in Treating Patients With Stage IV Non-small Cell Lung Cancer With Epidermal Growth Factor Receptor Mutations
ClinicalTrials.gov study NCT01532089. IPD Sharing: Not stated. Countries: 1. Publications: 1.
T-cell Receptor α/β Depleted Donor Lymphocyte Infusion
ClinicalTrials.gov study NCT05350163. IPD Sharing: NO. Countries: 1. Publications: 31.
CAR T Cell Receptor Immunotherapy Targeting VEGFR2 for Patients With Metastatic Cancer
ClinicalTrials.gov study NCT01218867. IPD Sharing: NO. Countries: 1. Publications: 3.
19(T2)28z1xx Chimeric Antigen Receptor (CAR) T Cells in People With B-Cell Cancers
ClinicalTrials.gov study NCT04464200. IPD Sharing: YES. Countries: 1. Publications: 2.
MCARH109 Chimeric Antigen Receptor (CAR) Modified T Cells for the Treatment of Multiple Myeloma
ClinicalTrials.gov study NCT04555551. IPD Sharing: YES. Countries: 1. Publications: 2.
A Study of Erlotinib (Tarceva) After Surgery With or Without Adjuvant Chemotherapy in Non-Small Cell Lung Carcinoma (NSCLC) Patients Who Have Epidermal Growth Factor Receptor (EGFR) Positive Tumors
ClinicalTrials.gov study NCT00373425. IPD Sharing: Not stated. Countries: 19. Publications: 1.
T Cells Expressing a Fully-human AntiCD19 Chimeric Antigen Receptor for Treating B-cell Malignancies
ClinicalTrials.gov study NCT02659943. IPD Sharing: NO. Countries: 1. Publications: 1.
T Cell Receptor Immunotherapy Targeting NY-ESO-1 for Patients With NY-ESO-1 Expressing Melanoma
ClinicalTrials.gov study NCT02062359. IPD Sharing: NO. Countries: 1. Publications: 3.
CAR T Cell Receptor Immunotherapy Targeting Mesothelin for Patients With Metastatic Cancer
ClinicalTrials.gov study NCT01583686. IPD Sharing: NO. Countries: 1. Publications: 3.
CAR T Cell Receptor Immunotherapy Targeting EGFRvIII for Patients With Malignant Gliomas Expressing EGFRvIII
ClinicalTrials.gov study NCT01454596. IPD Sharing: NO. Countries: 1. Publications: 5.
An Efficacy and Safety Study of a Combination of JNJ-73763989, Nucleos(t)Ide Analogs (NA), and a Programmed Cell Death Protein Receptor-1 (PD-1) Inhibitor in Chronic Hepatitis B Participants
ClinicalTrials.gov study NCT05275023. IPD Sharing: YES. Countries: 8. Publications: 0.
Oleclumab (MEDI9447) Epidermal Growth Factor Receptor Mutant (EGFRm) Non-small Cell Lung Cancer (NSCLC) Novel Combination Study
ClinicalTrials.gov study NCT03381274. IPD Sharing: YES. Countries: 3. Publications: 1.
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.